Maravai LifeSciences (MRVI) Stock Forecast & Price Target

$5.37 -0.06 (-1.10%)

(As of 12/20/2024 05:40 PM ET)

Maravai LifeSciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 11 Analyst Ratings

Sell
1

Hold
5

Buy
5

Based on 11 Wall Street analysts who have issued ratings for Maravai LifeSciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 1 has given a sell rating, 5 have given a hold rating, and 5 have given a buy rating for MRVI.

Consensus Price Target

$10.28
91.46% Upside

According to the 11 analysts' twelve-month price targets for Maravai LifeSciences, the average price target is $10.28. The highest price target for MRVI is $15.00, while the lowest price target for MRVI is $4.25. The average price target represents a forecasted upside of 91.46% from the current price of $5.37.

Get the Latest News and Ratings for MRVI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Maravai LifeSciences and its competitors.

MRVI Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.28	$10.33	$10.78	$13.50
Forecasted Upside	91.46% Upside	108.33% Upside	27.70% Upside	104.24% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

MRVI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRVI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Maravai LifeSciences Stock vs. The Competition

Type	Maravai LifeSciences	Medical Companies	S&P 500
Consensus Rating Score	2.36	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	91.46% Upside	25,828.93% Upside	14.52% Upside
News Sentiment Rating	Positive News See Recent MRVI News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/19/2024	Guggenheim 2 of 5 stars	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
12/5/2024	The Goldman Sachs Group 2 of 5 stars	M. Sykes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$7.00 ➝ $4.25	-21.44%
11/14/2024	Wolfe Research 3 of 5 stars	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/8/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$17.00 ➝ $13.00	+171.97%
11/8/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$10.00 ➝ $9.00	+14.80%
11/8/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
Get the Latest News and Ratings for MRVI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.
8/27/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00	+10.74%
8/13/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$11.00 ➝ $10.00	+14.94%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$8.50 ➝ $11.00	+37.33%
4/10/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$15.00	+76.26%
2/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$11.00 ➝ $10.00	+95.69%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$10.00 ➝ $8.00	+55.34%
8/8/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$23.00 ➝ $17.00	+52.60%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$14.00 ➝ $11.00	-0.18%
8/8/2023	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Sector Weight
5/23/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:26 AM ET.

MRVI Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Maravai LifeSciences is $10.28, with a high forecast of $15.00 and a low forecast of $4.25.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There is currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRVI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRVI, but not buy additional shares or sell existing shares.
: According to analysts, Maravai LifeSciences's stock has a predicted upside of 91.46% based on their 12-month stock forecasts.
: Over the previous 90 days, Maravai LifeSciences's stock had 1 downgrade by analysts.
: Maravai LifeSciences has been rated by research analysts at Guggenheim, Robert W. Baird, Royal Bank of Canada, The Goldman Sachs Group, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Maravai LifeSciences less than other "medical" companies. The consensus rating for Maravai LifeSciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRVI compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

This page (NASDAQ:MRVI) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Stock Forecast & Price Target